IPOs: Molecular Partners and Xenon pull off downsized debuts amid a shaky market

Damian Garde

Biotechs and Pharmaceuticals finally made their way to the public markets after previously postponing their , but each had to settle for a substantial discount in the process as investors continue to greet drug developers with skepticism.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS